Jeena Sikho Lifecare, a player in the healthcare sector, has made significant strides in its anti-diabetes research efforts. The company recently received approval to conduct clinical trials on four of its products, marking a potential breakthrough in diabetes management.

Products Under Trial

The company's research focus encompasses four distinct products:

1. SDM02 Tablets
2. Shuddhi XS Syrup
3. Petshuddhi Churna
4. Shuddhi Dr. B P Care Tablets

Promising Trial Results

According to the company's announcement, the clinical trials have yielded encouraging results. The products have demonstrated strong effectiveness in managing diabetes, a condition affecting millions worldwide. Notably, the trials reported no side effects, a factor that could potentially set these products apart in the competitive diabetes care market.

Implications for Diabetes Management

The approval for clinical trials and the positive initial results could have significant implications for Jeena Sikho Lifecare. If these products continue to show promise through further trials and eventual market release, they could offer new options for individuals managing diabetes.

The company's multi-product approach, spanning tablets, syrup, and traditional formulations like churna, suggests a comprehensive strategy to address various patient preferences and needs in diabetes care.

Looking Ahead

While these developments are promising, it's important to note that further research and regulatory approvals would be necessary before these products could potentially reach the market. Investors and stakeholders will likely be watching closely as Jeena Sikho Lifecare progresses with these clinical trials and advances its position in the diabetes care segment.

Jeena Sikho Lifecare Limited has announced the publication of three new case studies focusing on chronic kidney disease (CKD) management through Ayurvedic interventions. The company filed an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on December 30, 2025, regarding these academic publications.

New Research Publications on Kidney Health

The three studies have been published in the International Journal of Ayurveda and Herbal Research and the Journal of Applied Science and Education. These publications represent a shift in focus from the company's previous research on liver health and diabetes to specialized kidney disease management.

Clinical Outcomes and Patient Improvements

The case studies demonstrate significant improvements in patient outcomes across multiple parameters. The research involved patients with varying stages of CKD, including advanced cases with comorbidities such as hypertension, Type 2 diabetes, and coronary artery disease.

Comprehensive Treatment Approach

The studies showcase integrated treatment protocols combining Ayurvedic medicines, Panchakarma therapies, and lifestyle modifications. The research involved patients aged 50-57 years with varying durations of kidney disease, demonstrating the versatility of Ayurvedic interventions.

Key treatment components included specialized formulations such as Nefron Plus Capsules, CKD Tablets, and Renal Support Capsules, alongside traditional therapies like Basti, Shirodhara, and Abhyanga. The studies also emphasized the importance of dietary modifications and stress management techniques.

Research Team and Methodology

The publications were co-authored by Managing Director Acharya Manish Grover and a team of medical professionals including Dr. Gitika Chaudhary, Dr. Richa, Dr. Shivani Dhiman, Dr. Tanu Rani, Dr. Priyanka Biswas, Dr. Suyash Pratap Singh, and Dr. Shubham Badhan.

The research methodology involved comprehensive patient assessments, including Ashta-Vidh Pariksha (eight-fold examination), regular monitoring of vital parameters, and detailed documentation of treatment responses over extended periods.

Implications for Ayurvedic Medicine

These publications contribute to the growing body of evidence supporting Ayurvedic interventions in chronic disease management. The studies provide detailed documentation of treatment protocols, patient responses, and clinical outcomes, potentially influencing future research directions in integrative nephrology.

The research demonstrates the company's commitment to evidence-based Ayurvedic practice and its role in advancing scientific understanding of traditional medicine applications in modern healthcare settings.